U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H33ClN4O2.CH4O3S
Molecular Weight 613.167
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISPINESIB MESYLATE

SMILES

CS(O)(=O)=O.CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C2=NC3=CC(Cl)=CC=C3C(=O)N2CC4=CC=CC=C4

InChI

InChIKey=MRKSDPIHUJSKRA-HZPIKELBSA-N
InChI=1S/C30H33ClN4O2.CH4O3S/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22;1-5(2,3)4/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3;1H3,(H,2,3,4)/t27-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C30H33ClN4O2
Molecular Weight 517.062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ispinesib (SB-715992) is a potent, specific and reversible inhibitor of kinesin spindle protein (KSP). KSP, also known as HsEg5, is a kinesin that plays an essential role in the formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. Ispinesib is the highly specific small-molecule inhibitor of KSP tested for the treatment of human disease. It causes mitotic arrest and growth inhibition in several human tumor cell lines and is currently being tested in multiple phase II clinical trials for treatment of the breast cancer and renal cell cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
American Chemical Society--233rd National Meeting. Kinesin spindle protein inhibitors. 25-29 March 2007, Chicago, IL, USA.
2007 May
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
2007 Nov
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
2008 Jun
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
2008 Jun
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
2009 Dec 15
Functional characterisation and drug target validation of a mitotic kinesin-13 in Trypanosoma brucei.
2010 Aug 19
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
2010 Jan 15
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.
2010 Sep 28
Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
2011 Oct 13
Patents

Sample Use Guides

Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Route of Administration: Intravenous
In vitro, ispinesib at concentrations of 3.3 × 10−5 to 8.5 × 10−11 mol/L inhibited proliferation of all 53 breast cell lines tested. GI50 values spanned a 100-fold range and fall between 10 and 100 nmol/L for most cell lines. (The GI50 value is the drug concentration that results in 50% growth inhibition after 72 h of drug exposure relative to control). Ispinesib exhibited no apparent specificity for histopathologic subtype (luminal A, luminal B, basal) or receptor status (HER2, ER/PR).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:52:35 UTC 2023
Edited
by admin
on Fri Dec 15 15:52:35 UTC 2023
Record UNII
R6ZMD4UH3D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISPINESIB MESYLATE
USAN  
USAN  
Official Name English
CK0238273
Code English
ISPINESIB MESYLATE [USAN]
Common Name English
N-(3-AMINOPROPYL)-N-((1R)-1-(3-BENZYL-7-CHLORO-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)-2-METHYLPROPYL)-4-METHYLBENZAMIDE MONOMETHANESULPHONATE
Systematic Name English
BENZAMIDE, N-(3-AMINOPROPYL)-N-((1R)-1-(7-CHLORO-3,4-DIHYDRO-4-OXO-3-(PHENYLMETHYL)-2-QUINAZOLINYL)-2-METHYLPROPYL)-4-METHYL-, MONOMETHANESULFONATE
Systematic Name English
Ispinesib mesilate [WHO-DD]
Common Name English
SB-715992-S
Code English
CK-0238273
Code English
N-(3-Aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate
Systematic Name English
ISPINESIB MESILATE
WHO-DD  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67440
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
Code System Code Type Description
PUBCHEM
6450816
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
FDA UNII
R6ZMD4UH3D
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
SMS_ID
300000042482
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
CAS
514820-03-2
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL2111096
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
NCI_THESAURUS
C77518
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID70199455
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
USAN
QQ-11
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
DRUG BANK
DBSALT001998
Created by admin on Fri Dec 15 15:52:35 UTC 2023 , Edited by admin on Fri Dec 15 15:52:35 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY